Format

Send to

Choose Destination
Blood. 2015 Mar 19;125(12):1932-5. doi: 10.1182/blood-2014-07-590166. Epub 2015 Feb 2.

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Author information

1
St James's University Hospital, Leeds, United Kingdom;
2
University of Leeds, Leeds, United Kingdom;
3
Institute of Cancer Research, London, United Kingdom;
4
University of Birmingham, Birmingham, United Kingdom; and.
5
University of Newcastle, Newcastle, United Kingdom.

Abstract

The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival (OS). However, MRD level is a continuous variable, and the predictive value of the depth of tumor depletion was evaluated in 397 patients treated intensively in the Medical Research Council Myeloma IX study. There was a significant improvement in OS for each log depletion in MRD level (median OS was 1 year for ≥10%, 4 years for 1% to <10%, 5.9 years for 0.1% to <1%, 6.8 years for 0.01% to <0.1%, and more than 7.5 years for <0.01% MRD). MRD level as a continuous variable determined by flow cytometry independently predicts both PFS and OS, with approximately 1 year median OS benefit per log depletion. The trial was registered at www.isrctn.com as #68454111.

PMID:
25645353
PMCID:
PMC4375716
DOI:
10.1182/blood-2014-07-590166
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center